Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells

The paper is in-vitro in human cell cultures, not in-vivo in animal models or humans. The "rejuvenation" claim that surrounds KEDW in secondary writing — that the peptide reverses cellular aging or induces stem-cell-like states — is not what this paper demonstrates. What it reports is restoration of tissue-appropriate gene expression and partial reversal of age-associated DNA methylation patterns on selected promoters in aged cell cultures.

The Khavinson program publishes substantially within its own institutional network (St. Petersburg Institute of Bioregulation and Gerontology and collaborating Russian institutions). Independent Western replication of the KEDW gene-expression and methylation findings has not been reported. The 2015 American Journal of Biomedical Sciences companion paper extending the KEDW–DNA binding model (DOI 10.5099/aj150300156) is in a low-circulation venue without PubMed indexing, which limits cross-validation by Western readers.

The methylation findings are correlational with respect to the expression changes — promoter methylation correlates with expression for some genes and not for others, and the paper does not directly demonstrate that KEDW causes the methylation changes rather than acting downstream of them. The mechanism remains a hypothesis that this paper makes plausible but does not close.

The full body text was not directly accessible to the agent-pipeline extraction pass; specific numerical values for expression fold-changes, methylation percentages, peptide concentrations, and statistical tests are present in the paper's figures but were not retrievable here. A follow-up extraction pass with credentialed Springer / Pleiades library access would replace the abstract-and-companion-paper reconstruction with verbatim numerical data.

This is mechanism-of-action substrate, not outcome data. Translated into the corpus's evidence-tiering language: this is suggestive cell-culture mechanistic evidence for a short-peptide epigenetic-regulation hypothesis, parallel to and consistent with the Khavinson 2013 in-silico DNA-binding paper, but not equivalent to demonstrated in-vivo gene regulation in living tissue and certainly not equivalent to demonstrated clinical effect. The broader Khavinson corpus on this site (the Khavinson + Morozov 2002 / 2003 cohort, Anisimov-Khavinson 2001 mice, Khavinson 2003 telomerase) sits in the same single-laboratory-program evidence-depth landscape; this paper is the program's epigenetic-mechanism contribution to that landscape, not an independent line of evidence.

The peptides covered in the broader Khavinson program — Epitalon on this site, plus the not-yet-corpus-pages Vilon, Pancragen (KEDW), and the bronchial AEDL tetrapeptide — should be read as a single program with consistent in-house mechanism claims and a consistent absence of independent Western replication. Russian-language clinical work on parallel synthetic short peptides such as Semax and the broader cognitive-peptide cluster including Cerebrolysin is methodologically separate from the Khavinson short-peptide program even when the peptide structures look superficially similar.